Search results for: Rabbit Anti-Tetanus Toxin Antibodies
#29960800 2018/06/28 To Up
Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.
This study evaluated the immunogenicity and safety of quadrivalent meningococcal conjugate vaccine using tetanus (T) toxoid as carrier protein (MenACWY-TT) co-administered with combined diphtheria-tetanus-acellular pertussis vaccine (Tdap) versus their separate administration in adolescents and young adults.Luis Rivera, Tino F Schwarz, Kyung-Hyo Kim, Yun-Kyung Kim, Ulrich Behre, Sung-Ho Cha, Dae Sun Jo, Jacob Lee, Jin-Soo Lee, Brigitte Cheuvart, Archana Jastorff, Marie Van der Wielen
1058 related Products with: Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study.
100 mg1000 tests100ul25 mg10 mg500 MG200 25 mg100ug96T100ugRelated Pathways
#12678226 // To Up
Collaborative study for the establishment of two European Pharmacopoeia Biological Reference Preparations for serological potency testing of tetanus vaccines for veterinary use.
The European Directorate for the Quality of Medicines (EDQM) has organised an international collaborative study, divided into two phases, aimed at producing and establishing two suitable reference sera for serological potency testing of tetanus vaccines for veterinary use for batch consistency demonstration. In phase I pools of sera were produced by immunising guinea pigs and rabbits with tetanus toxoid using the immunisation schedule prescribed by the European Pharmacopoeia (Ph. Eur.) for potency testing of tenanus vaccines for veterinary use. Following aliquoting and freeze-drying, characterization of the materials by immunochemical and biological assays enabled us to conclude that the sera should be suitable reference materials in respect of in-vitro assay methods for Clostridium (C.) tetani. The candidate (c) Ph. Eur. Biological Reference Preparations (BRP) were calibrated by Toxin Binding Inhibition test (ToBI) in phase II of the study by a large group of laboratories, including both manufacturers and official medicines control laboratories (OMCL). The activity of the proposed reference sera was determined by comparison with the existing equine monovalent World Health Organization (WHO) International Standard (IS). This study enabled us to provide a definitive value for the antitoxin activity of the reference preparations in respect of their anti-tetanus antibody content.H H Lensing, M E Behr-Gross, A Daas, J M Spieser
1558 related Products with: Collaborative study for the establishment of two European Pharmacopoeia Biological Reference Preparations for serological potency testing of tetanus vaccines for veterinary use.
1 g100ug0.2 mg 1 G 25 G10 lt 1000 ml 1 G100 mg1 LITRERelated Pathways
#10225867 // To Up
Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A.
The C-terminal repeat domain of Clostridium difficile toxin A harbors toxin-neutralizing epitopes and is considered to be a candidate component of a vaccine against C. difficile-associated disease (CDAD). Fourteen of the 38 C-terminal toxin A repeats (14CDTA) were cloned into pTECH-1 in frame with the immunogenic fragment C of tetanus toxin (TETC) to generate plasmid p56TETC. Expression of the TETC-14CDTA fusion protein was driven from the anaerobically inducible nirB promoter within attenuated Salmonella typhimurium BRD509 (aroA aroD). The TETC-14CDTA fusion protein was purified and shown to bind to known toxin A receptors found on the surface of rabbit erythrocytes. Intranasal (i.n.) and intragastric (i.g.) immunization with 10(7) and 10(10) CFU, respectively, of BRD509(p56TETC) generated significant (P < 0.05) anti-toxin A serum responses after a single dose. Antibody titers were elevated following a boosting dose with either live vaccine or a subcutaneous injection of 0.5 microgram of purified 14CDTA protein. Importantly, serum from mice immunized with BRD509(p56TETC) neutralized toxin A cytotoxicity. Both i.n. and i.g. immunizations also generated toxin A-specific immunoglobulin A on the pulmonary and intestinal mucosa, respectively. Intranasal vaccination induced consistently higher serum and mucosal anti-toxin A antibody responses. Significant anti-tetanus toxoid serum and mucosal antibodies were also generated by both immunization routes. The availability of live attenuated Salmonella typhi for human use may allow the development of a multivalent mucosal vaccine against CDAD, tetanus, and typhoid.S J Ward, G Douce, D Figueiredo, G Dougan, B W Wren
1685 related Products with: Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A.
100 1 mg100 100ug Lyophilized100 100ug Lyophilized100ug Lyophilized200 ug100ug Lyophilized100ug Lyophilized1 mg100ug LyophilizedRelated Pathways
#1457823 // To Up
Experimental study on intradermal antitetanus antityphoid immunization.
A new type of concentrated unadsorbed Tetanus vaccine was administered in animals by intradermal route, associated or not with Typhoid vaccine. The results of the laboratory tests demonstrated that this vaccine is innocuous and produces minimal reactions. A single doses of Tetanus vaccine inoculated in guinea pig or rabbit resulted in a relevant titer which increased when the Typhoid vaccine was associated. Also, in such immunized guinea pigs, a remarkable resistance to tetanic toxin was achieved. The levels of the active or passive typhoid-protective power as well as that of the agglutinating antibodies were not influenced by the association of the Tetanus vaccine to the Typhoid vaccine. Therefore, when the Typhoid vaccine suspended in Tetanus vaccine was administered intradermally to the animals by Jet injector, it had not a negative effect for none of the two components, had a beneficial effect upon the levels of determined antibody production and allowed an easier and more rapid administration of these vaccines.G Dimache, C Stoean, S Durbacă, N Laşcu, M Croitoru, A Dimache
2704 related Products with: Experimental study on intradermal antitetanus antityphoid immunization.
6 ml Ready-to-use 5 mg lyophilized10 μg10 mg lyophilized 25 ml 25 MGRelated Pathways
#1988163 // To Up
Inhibition of human antigen-specific memory B cell response in vitro by a diphtheria toxin-related interleukin 2 fusion protein.
Recombinant diphtheria toxin-related interleukin-2 fusion protein (DAB486IL-2) is specifically cytotoxic for cells bearing the high-affinity IL-2 receptor (p55/75). We evaluated the effects of DAB486IL-2 on the generation of tetanus toxoid (TT)-specific IgG antibody-forming cells in 6-day cocultures of human splenocytes and TT-coupled Sepharose beads. The results indicate that a significant portion (30-75%) of the anti-tetanus toxoid IgG response in vitro was susceptible to inhibition by 10(-10) M DAB486IL-2. The inhibition required both the IL-2 portion of the fusion protein and an active toxin moiety and was greater when the IL-2 toxin was added on Day 3 as compared with Day 0 of culture. The induction of the p55 (Tac) subunit of the IL-2R was demonstrable by two-color flow cytometry on a small percentage (5%) of B cells and on a higher percentage (10%) of non-B cells 3 days after exposure to TT-coupled Sepharose. Short-term (2 hr) treatment of T and B cell subpopulations separated on Day 3 of culture followed by remixing indicated that while activated T helper cells were most strongly inhibited by DAB486IL-2, up to 50% of the TT-specific IgG response was inhibited by treatment of B cells alone with DAB486IL-2. Our results suggest that a strategy of eliminating human memory B cells by a combination of antigen activation and properly timed administration of a recombinant lymphokine-toxin fusion protein is feasible.A P Grailer, J C Nichols, T B Strom, H W Sollinger, W J Burlingham
2978 related Products with: Inhibition of human antigen-specific memory B cell response in vitro by a diphtheria toxin-related interleukin 2 fusion protein.
100ug Lyophilized100ug Lyophilized11 mg50ug25ml 96tests100ug Lyophilized500 50ug100ug Lyophilized0.05 mgRelated Pathways
#1718905 // To Up
The immune response to anti-idiotype antibodies bearing an internal image epitope of tetanus toxin/toxoid. II. Comparison of the primary humoral immune response to xenogeneic Ab2 beta 1 and Ab2 beta 2 internal image anti-idiotype antibodies.
Mouse monoclonal (Ab1) anti-tetanus toxin/toxoid antibodies were used to raise Ab2 beta (tetanus toxin/toxoid internal image bearing) anti-idiotype antibodies in rabbits. Those rabbit serum antibodies (Ab2 beta) that did not bind to mouse serum proteins on an affinity column gave rise to an Ab3 anti-tetanus toxin/toxoid antibody response in mice. Rabbit serum antibodies that did bind to the affinity column, when eluted and used to inoculate mice also gave rise to an Ab3 anti-tetanus toxin/toxoid antibody response. It is suggested that one population of rabbit Ab2 beta anti-idiotype antibodies (unbound fraction) bears a partial or complete internal image of a tetanus epitope (Ab2 beta 1) while others (bound fraction) bear a complete or partial mirror image of a mouse immunoglobulin epitope as well (Ab2 beta 2).D C Poskitt, S Turnbull, L Macdonald, M J Jean-François, D Yasmeen
2314 related Products with: The immune response to anti-idiotype antibodies bearing an internal image epitope of tetanus toxin/toxoid. II. Comparison of the primary humoral immune response to xenogeneic Ab2 beta 1 and Ab2 beta 2 internal image anti-idiotype antibodies.
0.5 ml1 mL1 ml100 μg100 μg1 mL1 mg100 1 ml100 μg1 mL1 mLRelated Pathways
#3301392 // To Up
Relation between protective potency and specificity of antibodies in sera of tetanus immunized individuals.
Out of 157 human sera analyzed for antitetanus antibody content by ELISA, 13 turned out to contain only anti-BIIb antibodies, of which 8 proved to be neutralizing. Of these, the 3 sera 303, 306 and 312 together with a commercially available standard preparation of human antitetanus immunoglobulins were further analyzed as to their antibody composition by ELISA using plates sensitized with either the toxoid or various tetanus toxin-derived fragments. It was verified that the protective potency of these antisera was related mainly to their anti-BIIb antibody content. Adsorption experiments confirmed that anti-BIIb antibodies were primarily involved in toxin neutralization, although the presence of high levels of both anti-alpha and anti-Ibc antibodies could confer neutralizing capacity on the sera. A rabbit antiserum raised with the BIIb fragment resulted in a neutralizing antiserum that allowed us to calibrate the ELISA with the anti-BIIb antibodies as International Units.M German-Fattal, A German, B Bizzini
2440 related Products with: Relation between protective potency and specificity of antibodies in sera of tetanus immunized individuals.
4 Membranes/Box100 μg100 μg100 μg100 μg100 μg100 μg100 2 Pieces/Box1 mgRelated Pathways
#6970218 // To Up
Multiple subsets of anti-tetanus toxoid antibody-producing cells in human peripheral blood differ by size, expression of membrane receptors, and mitogen reactivity.
C J Thiele, C D Morrow, R H Stevens
2900 related Products with: Multiple subsets of anti-tetanus toxoid antibody-producing cells in human peripheral blood differ by size, expression of membrane receptors, and mitogen reactivity.
100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized 100 UG100ug Lyophilized100ug Lyophilized100ug LyophilizedRelated Pathways
-
No related Items
#838750 // To Up
[In vivo titration of antidiphtheria and antitetanus antibodies at various levels].
E H Relyveld
2942 related Products with: [In vivo titration of antidiphtheria and antitetanus antibodies at various levels].
100 μg100 μg100 μg100 μg100 μg4 Membranes/Box100 μg100 μg4 Membranes/Box100 μg100 μg4 Membranes/BoxRelated Pathways
-
No related Items
#5606369 // To Up
[Behavior of antitetanus toxin in rabbits, following injection of tetanus antitoxin, injection of anatoxin or injection of antitoxin and anatoxin].
C Guasco
1342 related Products with: [Behavior of antitetanus toxin in rabbits, following injection of tetanus antitoxin, injection of anatoxin or injection of antitoxin and anatoxin].
5 G96 wellsRelated Pathways
-
No related Items
Contact Us:
Belgium
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
[email protected]
France
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
[email protected]
Germany
GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
[email protected]
United Kingdom
GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
[email protected]
Also in
Luxembourg +35220880274
Schweiz Züri +41435006251
Danmark +4569918806
Österreich +43720880899
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
Poland
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
[email protected]
skype gentaurpoland
Nederland
GENTAUR Nederland BV
Kuiper 1
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
[email protected]
Italy
GENTAUR SRL
IVA IT03841300167
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
[email protected]
Spain
GENTAUR Spain
Tel 0911876558
[email protected]
Bulgaria
GENTAUR Bulgaria
53 Iskar Str. 1191 Kokalyane, Sofia
Sofia 1000
Tel 0035924682280
Fax 0035929830072
[email protected]